

9-5-06

Express Mail Label No.: EV538965459US

Date of Deposit: August 31, 2006

Attorney Docket No. 33743-503CIP DIV3



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS : Bevilacqua et al.  
SERIAL NUMBER : 10/772,783 EXAMINER : Skowronek, Karlheinz R.  
FILING DATE : February 5, 2004 ART UNIT : 1631  
FOR : SYSTEMS AND METHODS FOR CHARACTERIZING A BIOLOGICAL CONDITION OR  
AGENT USING PRECISION GENE EXPRESSION PROFILES

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


**TRANSMITTAL LETTER**

Transmitted herewith for filing in the above-identified application are the following documents:

1. Revocation by Assignee and New Power of Attorney (2 pgs);
2. Schedule A (2 pgs); and
3. Return postcard.

The Commissioner is hereby authorized to charge any fee that may be due, or to credit any overpayment, to Deposit Account No. 50-0311, Reference No. 33743-503CIP DIV3. A duplicate copy of this transmittal letter is enclosed.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529  
Cynthia A. Kozakiewicz, Reg. No. 42,764  
Attorneys for Applicants  
c/o MINTZ, LEVIN  
Tel: (617) 542-6000  
Fax: (617) 542-2241  
Customer No. 30623

Date: August 31, 2006

Express Mail Label No.: EV538965459US

Date of Deposit: August 31, 2006

Attorney Docket No. 33743-503 CIP DIV 3



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

ASSIGNEE: Source MDX  
SERIAL NUMBER: See Attached Schedule A  
FILING DATE: See Attached Schedule A  
FOR: See Attached Schedule A

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


**REVOCATION BY ASSIGNEE AND NEW POWER OF ATTORNEY**

Source Precision Medicine, Inc. d/b/a Source MDX, a company and owner ("Assignee") of the patents and patent applications listed on the attached Schedule A, hereby revokes any and all former powers of attorney and hereby appoints the attorneys and/or agents associated with Mintz Levin Cohn Ferris Glovsky & Popeo, Customer Number 30623, as Applicants' attorneys with full power of substitution and revocation to take any and all action necessary with regard to the patent application.

Please address all telephone calls to Ivor R. Elrifi at telephone number 617/348-1747.  
Please address all correspondence to Customer No. 30623.

The undersigned is authorized to act on behalf of the Assignee in the above-referenced patent application.

Respectfully submitted,

  
NAME: KARL WASSMANN  
TITLE: CEO & PRESIDENT

COMPANY: SOURCE PRECISION MEDICINE, INC  
D/B/A SOURCE MDX

Date: 7/20/06

## Schedule A

### U.S. APPLICATIONS

Docket No.	Title	Serial No.	Filing or 371(c) Date	Assignment
33743-501	Systems and Methods for Characterizing a Biological Condition or Agent Using Precision Gene Expression Profiles	10/742,458	19-Dec-2003	Reel 014814 Frame 0980
33743-501 CIP2	Systems and Methods for Characterizing a Biological Condition or Agent Using Precision Gene Expression Profiles	10/781,558	17-Feb.-2004	Reel 014841 Frame 0216
33743-502	Quantitative Assay for Low Abundance Molecules	09/595,720	16-June- 2000	Reel 011174 Frame 0646
33743-503	Systems and Method for Characterizing a Biological Condition or Agent Using Calibrated Gene Expression Profiles	09/605,581	28-June-2000	Reel 011547 Frame 0141
33743-503 CIP	Systems and Methods for Characterizing a Biological Condition or Agent Using Precision Gene Expression Profiles	09/821,850	29-Mar-2001	Reel 015766 Frame 0994
33743-503 CIP2	Identification of Monitoring and Treatment of Disease and Characterization of Biological Condition Using Gene Expression Profiles	10/291,225	8-Nov-2002	Reel 014068 Frame 0793
33743-503 CIP DIV	Systems and Methods for Characterizing a Biological Condition or Agent Using Precision Gene Expression Profiles	10/703,143	03-Nov-2003	Reel 014816 Frame 0001

<b>33743-503 CIP DIV 2</b>	<b>Systems and Methods for Characterizing a Biological Condition or Agent Using Precision Gene Expression Profiles</b>	<b>10/701,391</b>	<b>03-Nov-2003</b>	<b>Reel 014825 Frame 0601</b>
<b>33743-503 CIP DIV 3</b>	<b>Systems and Methods for Characterizing a Biological Condition or Agent Using Precision Gene Expression Profiles</b>	<b>10/772,783</b>	<b>05-Feb-2004</b>	<b>Reel 014916 Frame 0953</b>
<b>33743-503 CIP DIV 4</b>	<b>Systems and Methods for Characterizing a Biological Condition or Agent Using Precision Gene Expression Profiles</b>	<b>10/778,594</b>	<b>13-Feb-2004</b>	<b>Reel 014840 Frame 0754</b>
<b>33743-503 CIP DIV 5</b>	<b>Systems and Methods for Characterizing a Biological Condition or Agent Using Precision Gene Expression Profiles</b>	<b>10/778,597</b>	<b>16-Feb-2004</b>	<b>Reel 015582 Frame 0332</b>
<b>33743-503 CIP DIV 6</b>	<b>Systems and Methods for Characterizing a Biological Condition or Agent Using Precision Gene Expression Profiles</b>	<b>10/778,603</b>	<b>16-Feb-2004</b>	<b>Reel 015560 Frame 0870</b>
<b>33743-503 CIP DIV 7</b>	<b>Systems and Methods for Characterizing a Biological Condition or Agent Using Precision Gene Expression Profiles</b>	<b>10/778,679</b>	<b>16-Feb-2004</b>	<b>Reel 015565 Frame 0852</b>
<b>33743-504</b>	<b>Identification, Monitoring and Treatment of Disease and Characterization of Biological Condition Using Gene Expression Profiles</b>	<b>10/291,856</b>	<b>08-Nov-2002</b>	<b>Reel 015624 Frame 0757</b>
<b>33743-504CON</b>	<b>Identification, Monitoring and Treatment of Disease and Characterization of Biological Condition Using Gene Expression Profiles</b>	<b>11/158,504</b>	<b>22-June-2005</b>	<b>Reel 015624 Frame 0757</b>
<b>33743-504CON2</b>	<b>Identification, Monitoring and Treatment of Disease and Characterization of Biological Condition Using Gene Expression Profiles</b>	<b>11/159,376</b>	<b>22-June-2005</b>	<b>Reel 015624 Frame 0850</b>
<b>33743-504CIP</b>	<b>Gene Expression Profiling for Identification Monitoring and Treatment of Multiple Sclerosis</b>	<b>11/155,930</b>	<b>16-June-2005</b>	<b>Reel 017072 Frame 0447</b>